Biocryst Pharmaceuticals (BCRX) EBIT Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 273.62% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.84% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -59.82% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 4.63% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -30.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 54.58% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 40.17% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -191.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -191.19% |
| Dec 31, 2025 | 96.80% |
| Sep 30, 2025 | 54.62% |
| Jun 30, 2025 | 41.91% |
| Mar 31, 2025 | 34.35% |
| Dec 31, 2024 | 55.79% |
| Sep 30, 2024 | 29.52% |
| Jun 30, 2024 | 31.93% |
| Mar 31, 2024 | 34.42% |
| Dec 31, 2023 | 6.62% |
| Sep 30, 2023 | 34.73% |
| Jun 30, 2023 | 18.69% |
| Mar 31, 2023 | 11.49% |
| Dec 31, 2022 | -651.77% |
| Sep 30, 2022 | 20.79% |
| Jun 30, 2022 | 0.19% |
| Mar 31, 2022 | -19.42% |
| Dec 31, 2021 | -27.35% |
| Sep 30, 2021 | -16.10% |
| Jun 30, 2021 | -17.47% |